Neurodegenerative disorders and methods of treatment and diagnosis thereof
This invention relates to compositions and methods for the therapy and diagnosis of neurodegenerative or neuromuscular disorders. More particularly, this invention relates to use of anaplerotic agents for treating, preventing, or delaying the onset of a neurodegenerative or neuromuscular disorder.
1. A method of treating amyotrophic lateral sclerosis (ALS) comprising administering to an animal with ALS a therapeutically effective amount of one or more precursors of propionyl-CoA, wherein the precursor of propionyl-CoA is selected from an uneven chain fatty acid, a triglyceride of an uneven chain fatty acid, a phospholipid comprising an uneven chain fatty acid, and a C5 ketone body.
2. The method of claim 1 , wherein the triglyceride of an uneven chain fatty acid is selected from tripentanoin, triheptanoin and trinonanoin.
3. The method of claim 2 , wherein the compound is triheptanoin.
4. The method of claim 1 , wherein the one or more precursors of propionyl-CoA are provided to the animal in an amount comprising at least about 5% of the dietary caloric intake for the animal.
5. The method of claim 4 , wherein the one or more precursors of propionyl-CoA are provided to the animal in an amount comprising at least about 20% of the dietary caloric intake for the animal.
6. The method of claim 5 , wherein the one or more precursors of propionyl-CoA are provided to the animal in an amount comprising at least about 30% of the dietary caloric intake for the animal.
7. The method of claim 6 , wherein the one or more precursors of propionyl-CoA are provided to the animal in an amount comprising at least about 35% of the dietary caloric intake for the animal.
8. The method of claim 1 , wherein the animal is an adult animal.
9. The method of claim 1 , wherein the animal is a mammal.
10. The method of claim 9 , wherein the mammal is a human.
11. The method of claim 1 , wherein the therapeutically effective amount of one or more precursors of propionyl-CoA is administered orally.
12. The method of claim 1 , wherein the C5 ketone body is selected from p-hydroxypentanoate and β-ketopentanoate.
13. The method of claim 1 , wherein the uneven chain fatty acid is selected from pentanoic acid, heptanoic acid, and nonanoic acid.
14. A method of treating amyotrophic lateral sclerosis (ALS) comprising administering to a subject with ALS a therapeutically effective amount of a seven carbon (C7) fatty acid source.
15. The method of claim 14 , wherein the seven carbon (C7) fatty acid source is selected from triheptanoin, heptanoic acid, heptanoate, a triglyceride comprising heptanoic acid, and a triglyceride comprising heptanoic acid and a fatty acid other than heptanoic acid.
16. The method of claim 15 , wherein the seven carbon (C7) fatty acid source is triheptanoin.
17. The method of claim 15 , wherein the fatty acid other than heptanoic acid is selected from pentanoic acid and nonanoic acid.
18. The method of claim 16 , wherein the triheptanoin is provided to the subject in an amount comprising at least about 20% of the dietary caloric intake for the subject.
19. The method of claim 16 , wherein the triheptanoin is provided to the subject in an amount comprising at least about 30% of the dietary caloric intake for the subject.
20. The method of claim 14 , wherein the subject is a human.